$RCEL earnings report

AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance. AlphAI read AVITA Medical's Third quarter 2026 filing as strong. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readRCEL · Third quarter 2026 · ended September 30, 2026

AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance

✓Strong quarter

Third-quarter total revenue increased 53% year over year and 20% sequentially to $26.1 million, gross margin expanded to 84.0%, net loss narrowed to $6.2 million, net cash use improved to approximately $0.6 million, and the Company raised full-year 2026 revenue guidance to $92 million to $94 million.

Revenue
$25.9M
RECELL
$22.4M
approximately 20% growth compared to Q2 2026 q/q
Gross margin · other
88.4%
Full-year 2026 outlook
$92 million to $94 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 sales revenueGAAP$25.86M––
Q3 2026 lease revenueGAAP$252K––
Q3 2026 total revenuesGAAP$26.11M20%53%
Q3 2026 cost of salesGAAP−$4.17M––
Q3 2026 gross profitGAAP$21.94M––
Q3 2026 gross profit margin across all productsother84.0%–270-basis point increase
Q3 2026 RECELL products gross marginother88.4%––
Q3 2026 sales and marketing expenseGAAP−$13.57M–$1.5 million increase
Q3 2026 general and administrative expenseGAAP−$6.31M–$0.9 million decrease
Q3 2026 research and development expenseGAAP−$4.70M–$1.0 million increase
Q3 2026 total operating expensesGAAP−$24.57Mflat7%
Q3 2026 operating lossGAAP−$2.63M––
Q3 2026 interest expenseGAAP−$1.48M––
Q3 2026 other expense, netGAAP−$2.05M––
Q3 2026 loss before income taxesGAAP−$6.16M––
Q3 2026 income tax expenseGAAP−$65K––
Q3 2026 net lossGAAP−$6.22M––
Q3 2026 net loss per common share, basic and dilutedGAAP$(0.20)––
Q3 2026 weighted-average common shares, basic and dilutedGAAP30,866,230––
Nine-month 2026 sales revenueGAAP$66.42M––
Nine-month 2026 lease revenueGAAP$652––
Nine-month 2026 total revenuesGAAP$67.07M––
Nine-month 2026 cost of salesGAAP−$11.63M––
Nine-month 2026 gross profitGAAP$55.44M––
Nine-month 2026 sales and marketing expenseGAAP−$39.98M––
Nine-month 2026 general and administrative expenseGAAP−$18.34M––
Nine-month 2026 research and development expenseGAAP−$15.40M––
Nine-month 2026 total operating expensesGAAP−$73.72M––
Nine-month 2026 operating lossGAAP−$18.29M––
Nine-month 2026 interest expenseGAAP−$4.37M––
Nine-month 2026 other expense, netGAAP−$1.76M––
Nine-month 2026 loss before income taxesGAAP−$24.41M––
Nine-month 2026 income tax expenseGAAP$(87)––
Nine-month 2026 net lossGAAP−$24.50M––
Nine-month 2026 net loss per common share, basic and dilutedGAAP$(0.80)––
Nine-month 2026 weighted-average common shares, basic and dilutedGAAP30,720,190––
Q3 2026 net cash useotherapproximately $0.6 millionimproved–

Segments

SegmentRevenueq/qy/y
RECELLHigher procedure volumes and increased account ordering.$22.4Mapproximately 20% growth compared to Q2 2026–
CohealyxAn expanding customer base and additional hospital value analysis committee (VAC) approvals.$2.1Mapproximately 21% growth compared to Q2 2026–
PermeaDermMaintained stable revenue; PermeaDerm I study results demonstrated comparable graft take and wound healing to allograft, with 70% lower product cost and 95.7% less preparation time.$600Kessentially flat compared to Q2 2026–
InternationalConsistent revenue from established international markets.$900Kessentially flat compared to Q2 2026–

Full-year 2026 outlook

  • Revenue$92 million to $94 million
  • NoteCash flow breakeven in the fourth quarter of 2026.
  • NoteRECELL products gross margin is currently expected to remain between 86% and 90% over the coming quarters.
  • NoteImplied fourth-quarter 2026 revenue of $24.9 to $26.9 million.
  • NoteUpdated full-year revenue range represents growth of approximately 28% to 31% compared with revenue of $71.6 million in 2025.

What drove it

  • Total revenue growth was led by RECELL and supported by Cohealyx and PermeaDerm.
  • Higher RECELL revenue and improvements in manufacturing efficiency supported the 84.0% gross margin.
  • RECELL growth reflected higher procedure volumes and increased account ordering.
  • Cohealyx growth reflected an expanding customer base and additional hospital VAC approvals.
  • Operating-expense growth was largely driven by higher sales and marketing expenses, principally increased commissions and compensation including annual incentive costs.
  • On November 4, 2026, the Centers for Medicare & Medicaid Services finalized national physician payment values and simplified billing codes for RECELL procedures, effective January 1, 2027.

Concerns

  • Q3 2026 net loss remained $(6,222), and nine-month 2026 net loss was $(24,496).
  • Current liabilities were $23,037 and total stockholders' equity (deficit) was $(31,037) as of September 30, 2026.
  • Net loss for the current period was negatively impacted by $2.1 million in non-cash expense related to the revaluation of warrants due to the increase in AVITA Medical’s share price.
  • The Company receives 50% of the average sales price for Cohealyx and up to 55% for PermeaDerm, which lowers the overall gross margin percentage.
  • The Company cited risks including variability in volumes and hospital ordering patterns, reimbursement implementation, receivables and working-capital management, credit-facility covenant compliance, and product mix and manufacturing costs.

What to watch

  • Fourth-quarter revenue implied by full-year guidance of $24.9 to $26.9 million.
  • Achievement of cash flow breakeven in the fourth quarter of 2026.
  • RECELL products gross margin expected to remain between 86% and 90% over the coming quarters.
  • Commercial adoption of Cohealyx following additional hospital VAC approvals.
  • Implementation of the national physician payment values and simplified RECELL billing codes effective January 1, 2027.
  • The liquidity effect of the $10.0 million credit-facility tranche drawn subsequent to quarter-end.

Balance sheet and cash flow

  • Cash and cash equivalents were $10,500 as of September 30, 2026, compared with $10,243 as of December 31, 2025.
  • Marketable securities were $0 as of September 30, 2026, compared with $7,942 as of December 31, 2025.
  • Cash, cash equivalents and marketable securities totaled approximately $10.5 million at September 30, 2026, compared with $11.1 million at the beginning of the quarter.
  • Accounts receivable, net were $10,343 as of September 30, 2026, compared with $9,086 as of December 31, 2025.
  • Inventory was $4,803 as of September 30, 2026, compared with $6,926 as of December 31, 2025.
  • Total assets were $46,794 as of September 30, 2026, compared with $56,392 as of December 31, 2025.
  • Loan facility, long-term was $45,476 as of September 30, 2026; loan facility was $42,984 as of December 31, 2025.
  • Subsequent to quarter-end, the Company drew the remaining $10.0 million tranche, bringing total borrowings under the facility to $60 million.
  • Total liabilities were $77,831 as of September 30, 2026, compared with $73,042 as of December 31, 2025.
  • Total stockholders' equity (deficit) was $(31,037) as of September 30, 2026, compared with $(16,650) as of December 31, 2025.

Analysis

AVITA reported a strong third quarter, with GAAP total revenues of $26,114 versus $17,062 in the prior-year period. The release also described revenue as up 53% year over year and 20% sequentially. RECELL generated $22.4 million of Q3 U.S. revenue and grew approximately 20% versus Q2 2026, supported by higher procedure volumes and increased account ordering. Cohealyx generated $2.1 million and grew approximately 21% sequentially as its customer base expanded and hospital VAC approvals increased.

Product mix and manufacturing execution supported profitability. Gross profit was $21,941 versus $13,875, while gross profit margin across all products reached 84.0%, up 270 basis points from 81.3%. RECELL products gross margin was 88.4%. Management said that Cohealyx and PermeaDerm lower overall gross-margin percentage because the Company receives 50% of the average sales price for Cohealyx and up to 55% for PermeaDerm.

Expense control improved operating leverage despite commercial compensation costs. Total operating expenses were $(24,570), up 7% from $(23,028) in the prior-year period and described as flat to the prior quarter. Sales and marketing expense increased to $(13,566), research and development expense increased to $(4,697), and general and administrative expense declined to $(6,307). Operating loss narrowed to $(2,629) from $(9,153), while net loss narrowed to $(6,222), or $(0.20) per basic and diluted share, from $(13,187), or $(0.46) per basic and diluted share. The current-period loss included $2.1 million of non-cash warrant revaluation expense.

Liquidity remained central to the quarter. Net cash use improved to approximately $0.6 million from $3.2 million in Q2 2026, and cash, cash equivalents and marketable securities were approximately $10.5 million at September 30, 2026. The Company reached at least $85.0 million of trailing-twelve-month revenue, enabling access to the remaining $10.0 million under its Perceptive Advisors LLC credit facility. It drew that tranche after quarter-end, bringing total borrowings under the facility to $60 million, and management said the going-concern qualification was removed in the Quarterly Report on Form 10-Q.

Management raised full-year 2026 revenue guidance to $92 million to $94 million from $86 million to $89 million and reaffirmed its expectation of cash flow breakeven in Q4 2026. The updated full-year range implies fourth-quarter revenue of $24.9 to $26.9 million. The principal operating markers are sustained RECELL procedure and account growth, further Cohealyx adoption, maintenance of expected RECELL gross margin between 86% and 90%, and delivery of the stated fourth-quarter cash flow breakeven target.

Management, verbatim

AVITA delivered another strong quarter, with revenue increasing 53% year over year and gross margin reaching 84%. RECELL continued to drive our growth, supported by increasing adoption of Cohealyx, while disciplined expense management contributed to a substantial improvement in cash use. Based on our year-to-date performance and continued commercial momentum, we are raising our full-year revenue guidance and remain on track to achieve cash flow breakeven in the fourth quarter.

Cary Vance, President and Chief Executive Officer of AVITA Medical

Reaching $85 million in trailing twelve-month revenue reflects the continued execution of our commercial strategy and satisfied the revenue condition required to draw down the remaining $10 million under our credit facility with Perceptive Advisors LLC. This additional, minimally dilutive capital strengthens our liquidity as we advance toward cash flow breakeven and cash generation in the fourth quarter. Based on our improved operating performance and liquidity, management concluded that the substantial doubt about our ability to continue as a going concern has been alleviated. Accordingly, the outstanding debt under the credit facility is now classified as a long-term liability on our balance sheet.

David O'Toole, Chief Financial Officer

Not in the filing

stated, not guessed
  • Non-GAAP revenue, gross profit, operating income, net income, and EPS were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Full-year 2026 gross margin, operating-expense, and tax-rate guidance were not reported.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readRCEL · Second Quarter 2026 · ended June 30, 2026

AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven

✓Solid quarter

Record revenue grew 18% year over year and 13% sequentially, gross margin expanded, operating expenses declined, net loss narrowed, and the Company raised full-year 2026 revenue guidance while expecting fourth-quarter cash flow breakeven.

Revenue
approximately $21.7 million
18% y/y · 13% q/q
RECELL
$18.5M
approximately 11% growth compared to Q1 2026 q/q
Gross margin · other
86.0%
full-year 2026 outlook
$86 million to $89 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueotherapproximately $21.7 million13%18%
Gross profit marginother81.9%–an increase of 70 basis points year-over-year
RECELL-only gross marginother86.0%––
Operating expensesother$24.6M–down 6% or $1.5 million
Net lossother$7.7M––
Net loss per basic and diluted shareothera loss of $0.25 per basic and diluted share––
Net cash useotherapproximately $3.2 million––
Cash, cash equivalents, and marketable securitiesotherapproximately $11.1 million––
2025 revenueother$71.6M––

Segments

SegmentRevenueq/qy/y
RECELLSequential growth was supported by increasing physician confidence following reimbursement stabilization and continued adoption of RECELL GO mini, which expanded utilization in smaller wounds.$18.5Mapproximately 11% growth compared to Q1 2026–
CohealyxGrowth was supported by favorable interim clinical data from the Cohealyx I clinical study reported in April demonstrating a faster time to skin grafting readiness than leading competitive products.$1.7Mapproximately 16% growth compared to Q1 2026–
PermeaDermPermeaDerm gained traction during the second quarter as an alternative to allograft to temporarily stabilize and protect the wound before definitive closure.$600Kapproximately 40% growth compared to Q1 2026–
InternationalEstablished international markets continued to contribute consistent revenue.$900Kapproximately 26% growth compared to Q1 2026–

full-year 2026 outlook

  • Revenue$86 million to $89 million
  • Noteyear-over-year growth in the range of 20% to 24%
  • Noteexpects to achieve cash flow breakeven in the fourth quarter of 2026

What drove it

  • Total revenue growth was driven by continued execution across the commercial portfolio, led by RECELL and supported by Cohealyx and PermeaDerm.
  • Gross profit margin reflected RECELL growth alongside expansion of the product portfolio.
  • Operating expense reductions reflected cost optimization initiatives and commercial restructuring actions implemented in 2025.
  • Sales and marketing expenses decreased by $0.7 million, and general and administrative expenses decreased by $0.7 million.
  • Research and development expenses were flat with the prior-year period.
  • Improved timely customer cash collections are expected to support the path to cash flow breakeven.

Concerns

  • The Company reported a net loss of $7.7 million and expects cash flow breakeven only in the fourth quarter of 2026.
  • The Company shares the average sales price for Cohealyx at 50% and for PermeaDerm at 60%, which it said inevitably results in an overall decrease in gross margin percentage.
  • The proposed 2027 Medicare payment updates for RECELL remain subject to final CMS rules.
  • Availability of the additional $10 million credit-facility tranche is contingent on achieving at least $85 million of trailing twelve-month net revenue in any month prior to March 31, 2027.

What to watch

  • Execution toward full-year 2026 net revenue guidance of $86 million to $89 million.
  • Achievement of expected cash flow breakeven in the fourth quarter of 2026.
  • Presentation of PermeaDerm I study data in August.
  • CMS final rules later this year and implementation effective January 1, 2027.
  • Progress toward at least $85 million of trailing twelve-month net revenue needed for the additional credit-facility tranche.

Balance sheet and cash flow

  • Net cash use improved to approximately $3.2 million, from $9.9 million in Q1 2026.
  • Cash, cash equivalents, and marketable securities were approximately $11.1 million at the end of the quarter, compared with $14.3 million at the beginning of the quarter.
  • Under the existing credit facility, an additional tranche of $10 million remains available upon achieving at least $85 million of trailing twelve-month net revenue in any month prior to March 31, 2027.

Analysis

AVITA reported record second-quarter revenue of approximately $21.7 million, up 18% from the prior-year period and 13% sequentially. RECELL remained the principal commercial contributor at $18.5 million, while Cohealyx, PermeaDerm, and international revenue each posted sequential growth. Management attributed RECELL growth to increasing physician confidence following reimbursement stabilization and continued RECELL GO mini adoption in smaller wounds.

The quarter showed favorable reported margin and cost trends. Gross profit margin was 81.9%, compared with 81.2% in the prior-year period, and RECELL-only gross margin was 86.0%. The Company noted that its average-sales-price sharing arrangements for Cohealyx and PermeaDerm, at 50% and 60%, respectively, inevitably reduce the overall gross-margin percentage as those products expand. This makes portfolio mix an important factor alongside revenue growth.

Operating expenses declined 6%, or $1.5 million, to $24.6 million, reflecting cost optimization and commercial restructuring actions implemented in 2025. Sales and marketing expenses decreased by $0.7 million, general and administrative expenses decreased by $0.7 million, and research and development expenses were flat with the prior-year period. The lower expense base, together with revenue growth, coincided with a narrower net loss of $7.7 million, versus $9.9 million in the prior-year period.

Cash use also improved. Net cash use was approximately $3.2 million, compared with $9.9 million in Q1 2026, while cash, cash equivalents, and marketable securities were approximately $11.1 million at quarter-end compared with $14.3 million at the beginning of the quarter. Management expects improved timely customer cash collections, high gross margins, and expense management to support cash flow breakeven and cash generation in the fourth quarter of 2026. The Company also has a conditional additional $10 million credit-facility tranche tied to at least $85 million of trailing twelve-month net revenue before March 31, 2027.

Management raised full-year 2026 revenue guidance to $86 million to $89 million from $80 million to $85 million and reiterated an expected path to fourth-quarter cash flow breakeven. The Company cited proposed CMS calendar-year 2027 updates that could establish national physician payment for RECELL and increase hospital outpatient and ambulatory surgical center facility payment rates if finalized. Near-term operating milestones include the expected August presentation of PermeaDerm I study data and CMS final rules expected later this year.

Management, verbatim

We delivered a strong second quarter, with revenue growing 18% year-over-year and 13% sequentially. As AVITA continues to expand utilization in the U.S. and build its presence in key international markets, our results reflect the strength of both our acute wound care portfolio and our commercial execution, led by RECELL and supported by Cohealyx and PermeaDerm.

Cary Vance, President and Chief Executive Officer of AVITA Medical

During the second quarter, we maintained a disciplined approach to operating expenses while delivering record revenue and, as expected, a further reduction in net use of cash. As the business continues to scale, supported by sustained high gross margins, operating expense management, and improved timely customer cash collections, we expect to reach cash flow breakeven and to start generating cash in the fourth quarter of 2026.

David O'Toole, Chief Financial Officer

Not in the filing

stated, not guessed
  • GAAP and non-GAAP basis labels or reconciliations for reported revenue, gross margin, operating expenses, net loss, and loss per share
  • Gross profit in dollars
  • Operating income or operating loss
  • Operating cash flow
  • Free cash flow
  • Debt balance
  • Tax expense and tax rate
  • Diluted weighted-average shares outstanding
  • Share repurchases
  • Dividends
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, earnings, or earnings per share
  • Prior-quarter total revenue amount
  • Prior-year revenue comparisons for RECELL, Cohealyx, PermeaDerm, and International

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about RCEL earnings dates

When is AVITA Medical's next earnings date?
AlphAI has no date for RCEL yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.